Effects of chemotherapy on the auditory system of children with cancer: a systematic literature review
Efeitos do tratamento quimioterápico no sistema auditivo de crianças com câncer: revisão sistemática da literatura
Nila Bernardes Lopes; Liliane Aparecida Fagundes Silva; Alessandra Giannella Samelli; Carla Gentile Matas
Abstract
Purpose: to identify and analyze the effects of chemotherapy on the auditory system of children and/or adolescents with cancer treated with cisplatin and carboplatin, assessed through standardized audiological procedures.
Methods: studies in Brazilian Portuguese and in English were searched for, as available in the databases Science Direct, PubMed, LILACS, BIREME, Embase, SciELO, Web of Science and Cochrane. The descriptors were: Hearing Loss, Audiology, Child Cancer, Chemotherapy, and Child. Articles with levels 1 and 2 of scientific evidence, published in the last 20 years (1997 to 2017), were considered, of which the audiological results were analyzed, as well as the prevalence of hearing loss in children with cancer undergoing chemotherapy.
Results: 3,625 articles were found, of which only 23 were selected for analysis in the present review. Studies have shown a high incidence of sensorineural hearing loss and decrease or even loss of otoacoustic emissions in children and adolescents with cancer, even after the first dose of chemotherapy drugs, with high frequencies being the most affected.
Conclusion: there is evidence that both carboplatin and especially cisplatin from the first doses may impair the hearing of children and adolescents, mainly affecting the cochlear function, thus, the importance of long-term audiological monitoring.
Keywords
Resumo
Objetivo: identificar e analisar os efeitos da quimioterapia no sistema auditivo de crianças e/ou adolescentes com câncer tratados com cisplatina e carboplatina, avaliados por meio de procedimentos audiológicos padronizados.
Métodos: buscou-se por estudos nos idiomas português brasileiro e inglês, disponíveis nas bases de dados Science Direct, PubMed, Lilacs, Bireme, Embase, Scielo, Web of Science e Cochrane. Os descritores foram: Perda Auditiva, Audiologia, Câncer Infantil, Quimioterapia e Criança. Foram considerados artigos com níveis de evidência científica 1 e 2, publicados nos últimos 20 anos (1997 a 2017), dos quais foram analisados os resultados audiológicos, bem como a prevalência da perda auditiva de crianças com câncer submetidas à quimioterapia.
Resultados: foram encontrados 3625 artigos, sendo que apenas 23 foram selecionados para análise na presente revisão. Os estudos demonstraram alta incidência de perda auditiva neurossensorial e diminuição ou até perda das emissões otoacústicas em crianças e adolescentes com câncer, mesmo após a primeira dose das drogas quimioterápicas, sendo que as frequências altas são as mais acometidas.
Conclusões: há evidências de que a carboplatina e especialmente a cisplatina, desde as primeiras doses, podem prejudicar a audição de crianças e adolescentes, afetando principalmente a função coclear, destacando a importância do monitoramento audiológico a longo prazo.
Palavras-chave
Referências
1. Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância Estimativa 2016: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva – Rio de Janeiro: INCA, 2015. Disponível em: http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf.
2. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53.
3. Warwick GP. The mechanism of action of alkylating agents. Cancer Res. 1963;23:1315-33.
4. Silva AM, Latorre MRDO, Cristofani LM, Odone Filho V. The prevalence of hearing loss in children and adolescents with cancer. Braz J Otorhinolaryngol. 2007;73(5):608-14.
5. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2012:CD009219.
6. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005;10(19):1313-21.
7. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016 Aug 3:CD010181.
8. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649-55.
9. Almeida EOC, Umeoka WG, Viera RC, Moraes FI. High frequency audiometric study in cancer-cured patients treated with cisplatin. Braz J Otorhinolaryngol. 2008;74(3):382-90.
10. Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest. 2005;23(3):201-7.
11. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: in influence of age and cumulative dose. Eur. J. Cancer. 2004;40(16):2445-51.
12. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47(2)183-93.
13. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-4.
14. Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 2012;295(11):1851-67.
15. Stern JN, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol. 2002;39(3):163-7.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med. 2009:151(4):264-9.
17. Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Lat Am Enfermagem. 2007;15(3):508-11.
18. Oxford Centre for Evidence-based Medicine – Levels of Evidence. Março de 2009. Disponível em: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Acesso em: 01 de Agosto de 2016.
19. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ.2011;343:d5928.
20. Berg AL, Spitzer JB, Gamin JH. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109(11):1806-14.
21. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions - an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59(1):47-57.
22. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355-60.
23. Schmidt CM, Knief A, Lagosch AK, Deuster D, Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Ear Hear. 2008;29(6):830-7.
24. Al-Noury K. Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin. Laryngoscope. 2011;121(5):1081-4.
25. Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Int J Pediatr Otorhinolaryngol. 2012;76(1):131-6.
26. Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A et al. Hearing loss in Mexican children treated with cisplatin. Int J Pediatr Otorhinolaryngol. 2014;78(9):1456-60.
27. Liberman PH, Goffi-Gomez MV, Schultz C, Novaes PE, Lopes LF. Audiological profile of patients treated for childhood cancer. Braz J Otorhinolaryngol. 2016;82(6):623-9.
28. Smits C, Swen SJ, Goverts ST, Moll AC, Imhof SM, Meeteren AYNS. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer. 2006;42(4):492-500.
29. Amorim AM, Azevedo MF, Carvalho CAF, Macedo CRPD. Transient otoacoustic emissions in childrens with retinoblastoma submitted to chemotherapy with carboplatin. Int Arch Otorhinolaryngol. 2007;11(4):375-9.
30. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50(2):223-6.
31. Bhagat SP, Bass JK, White ST, Qaddoumi I, Wilson MW, Wu J et al. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol. 2010;74(10):1156-63.
32. Bhagat SP, Bass JK, Qaddoumi I, Brennan R, Wilson M, Wu J et al. Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy. Audiol Neurootol. 2013;18(2):71-82.
33. Knight KR, Kraemer DF, Winter C, Neuwelt AE. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190-5.
34. Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913-9.
35. Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M et al. Long term hearing degeneration after platinum based chemotherapy in childhood. Int J Audiol. 2010;49(10):765-71.
36. Einar-Jon E, Trausti O, Asgeir H, Christian M, Thomas W, Måns M et al. Hearing impairment after platinum-based chemotherapy in childhood. Pediatr Blood Cancer. 2011;56(4):631-7.
37. Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret A et al. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer. 2014;61(11):2012-7.
38. Clemens E, Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Eur J Cancer. 2016;69:77-85.
39. Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G et al. Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurootol. 2016;21(4):203-11.
40. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol. 2017;274(3):1187-96.
Submetido em:
09/09/2019
Aceito em:
29/11/2019
Facebook
Twitter
LinkedIn
Mendeley
Email